Legend Biotech Corporation Website

Legend Biotech Corporation

NasdaqGS-LEGN

Basic

  • Market Cap

    $10.78B

  • EV

    $9,812.55M

  • Shares Out

    182.28M

  • Revenue

    $342.8M

  • Employees

    2,000

Margins

  • Gross

    -63.84%

  • EBITDA

    -124.09%

  • Operating

    -127.12%

  • Pre-Tax

    -136.5%

  • Net

    -135.92%

  • FCF

    -76.02%

Returns (5Yr Avg)

  • ROA

    -44.91%

  • ROTA

    -220.69%

  • ROE

    -204.57%

  • ROCE

    -50.84%

  • ROIC

    -112.19%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $82.63

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    $1,302.38M

  • Net Debt

    -$967.69M

  • Debt/Equity

    0.29

  • EBIT/Interest

    -19.67

Growth (CAGR)

  • Rev 3Yr

    62.15%

  • Rev 5Yr

    41.94%

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    -1.33%

  • Dil EPS 5Yr

    154%

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    89.42%

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Select a metric from the list below to chart it

Dec '17

Dec '18

Jan '20

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Metric
Dec '17
Dec '18
Jan '20
Dec '20
Dec '21
Dec '22
Dec '23
LTM

Operating Revenues

60

75

65.4

116.7

285

339.3

Other Revenues, Total

1.8

—

3.4

0.3

0.2

3.5

Total Revenues

61.8

75

68.8

117

285.1

342.8

Total Revenues % Chg.

—

24.9%

21.4%

-8.2%

70%

143.7%

206%

Cost of Goods Sold, Total

—

—

—

232.2

313.3

401

526.4

561.6

Gross Profit

61.8

-157.2

-244.5

-284

-241.3

-218.8

Selling General & Admin Expenses, Total

32.4

72.7

149.5

174

200.9

216.9

R&D Expenses

161.9

—

—

—

—

—

Other Operating Expenses, Total

194.3

72.7

149.5

174

200.9

216.9

Operating Income

-132.5

-229.9

-394

-458.1

-442.2

-435.8

Interest Expense, Total

-0.2

-0.2

-0.9

-10.8

-21.8

-22.2

Interest And Investment Income

4.6

2.9

1

8.2

54.5

61.6

Net Interest Expenses

4.4

2.7

0.1

-2.6

32.7

39.4

Currency Exchange Gains (Loss)

—

0.6

0.1

—

—

—

49.1

Other Non Operating Income (Expenses)

-0.2

-1.2

-12.3

14.8

-111

-120.9

EBT, Excl. Unusual Items

-127.8

-228.3

-406.2

-445.8

-520.6

-468.1

Gain (Loss) On Sale Of Investments

—

0.5

0

—

0.6

0.7

0.4

Gain (Loss) On Sale Of Assets

—

—

—

-0.1

-1

-0.5

-0.2

-0.2

Other Unusual Items

—

—

—

-80

—

—

—

—

EBT, Incl. Unusual Items

-127.3

-308.3

-407.2

-445.7

-520.1

-467.9

Income Tax Expense

-25.7

-41.9

-3.6

0.6

-1.9

-2

Earnings From Continuing Operations

-101.6

-266.4

-403.6

-446.3

-518.3

-465.9

Net Income

-101.6

-266.4

-403.6

-446.3

-518.3

-465.9

Net Income to Common Incl Extra Items

-101.6

-266.4

-403.6

-446.3

-518.3

-465.9

Net Income to Common Excl. Extra Items

-101.6

-266.4

-403.6

-446.3

-518.3

-465.9

Total Shares Outstanding

100

133

154.2

165.1

181.9

182.3

Weighted Avg. Shares Outstanding

100

118.2

140.9

159

176.1

180.3

Weighted Avg. Shares Outstanding Dil

100

118.2

140.9

159

176.1

180.3

EPS

-1

-2.3

-2.9

-2.8

-2.9

-2.6

EPS Diluted

-1

-2.3

-2.9

-2.8

-2.9

-2.6

EBITDA

-129.4

-223.6

-385.9

-447.9

-431.5

-425.4

Effective Tax Rate

20.2%

13.6%

0.9%

-0.1%

0.4%

0.4%